Skip to content

COMPARATIVE REPERTORAIL ANALYSIS OF MIGRAINE USING BBCR AND SYNTHESIS REPERTORY- A RANDOMISED SINGLE BLIND TRIAL

Comparative Repertorial Analysis of Migraine Using Boger-Boenninghausen s Characteristics and Repertory and Synthesis Repertory: A Randomized Single-Blind Clinical Trial - COMPARative Evaluation in MIGraine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/108578
Enrollment
52
Registered
2026-04-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G431- Migraine with aura

Interventions

Intervention1: Individualized Homoeopathic Treatment Based on BBCR Repertory: Patients in this group will undergo detailed homoeopathic case taking. Repertorial analysis will be performed using BBCR r

Sponsors

Dr Sanket khutwad
Lead Sponsor
Dr Priya R Sheth
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. The Patients with the complaints of mild migraine assessed by Midas scales will be included 2. Age group between 12 years -40 years 3. Both the sexes male and female. 4. Patient who are having controlled Diabetes and hypertension HbA1C -7

Exclusion criteria

Exclusion criteria: 1. Patients having severe migraine to Midas scale and co-morbidities like Thyroid . 2. Patients having other co-morbidities excluded DM and hypertension .

Design outcomes

Primary

MeasureTime frame
The primary outcome of the study was the reduction in frequency of migraine attacks per month after individualized homoeopathic treatment over a follow-up period of 3 months.Timepoint: The primary outcome of the study was the reduction in frequency of migraine attacks per month after individualized homoeopathic treatment over a follow-up period of 3 months.

Secondary

MeasureTime frame
Secondary outcomes included reduction in pain intensity measured by Visual Analogue Scale (VAS), decrease in duration of migraine episodes, improvement in MIDAS disability score, and reduction in associated symptoms such as nausea, vomiting, photophobia, and phonophobia.Timepoint: Secondary outcomes including pain intensity (VAS score), duration of migraine attacks, MIDAS disability score, and associated symptoms were assessed at baseline, 4 weeks, 8 weeks, and 12 weeks during the treatment period.

Countries

India

Contacts

Public ContactDr Priya R Sheth

Bharati Vidyapeeth deemed to be university

Khutwadsanket146@gmail.com9552762301

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026